REDONDO BEACH, CA--(Marketwired - Sep 13, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article examining the potential of the newly-launched brain health supplement RecalMax™.
Innovus Pharma's (OTCQB: INNV) RecalMax™ was tested in a four-month human clinical trial on 72 patients with low memory and learning. After taking one capsule twice a day for 16 weeks, patients reported a 115% increase in the recall of words and names, a 49.5% increase in maintaining thoughts when distracted, and a 35% increase in processing speed. The supplement was also well-tolerated with no serious adverse events reported.
Parkinson's disease and Alzheimer's disease are the two most prevalent medical conditions falling into the neurodegenerative market, estimated in the neighborhood of $11 billion annually. Both are characterized by neurological problems affecting memory, learning, and nerve function -- eventually leading to premature death.
Innovus Pharma estimates that the immediate market for a product like RecalMax™ could be worth around $3 billion, since it helps treat some of the major endpoints associated with neurodegenerative diseases. Management believes that it can capture enough of the market to generate about $5 million in annual revenue by deploying the treatment across its well-established Beyond Human Platform and online marketing channels throughout the U.S. and other regions of the world.
To read the full article, please click here: http://analysis.secfilings.com/articles/64-innovus-pharma-innv-s-recalmax-could-be-the-best-complementary-supplement-for-aricept-and-namenda-s-11-billion-neurodegenerative-market
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.